BioNTech Drops $800m To Acquire Bispecific Specialist Biotheus
The German group is doubling down on the hot PD-(L)1 x VEGF-A bispecific space but will still have to contend with Summit and Akeso’s more advanced rival.
The German group is doubling down on the hot PD-(L)1 x VEGF-A bispecific space but will still have to contend with Summit and Akeso’s more advanced rival.